LifeArc Ventures’ billion-pound investment strategy appears to be paying off, as the British life sciences VC fund saw its first portfolio company sold off in the form of Ducentis BioTherapeutics. LifeArc has been the biggest investor in Ducentis and its asset DS-234, which is being developed for the treatment of atopic dermatitis. Source: Fierce Biotech 8/9/2022